AJ, S., H, X., S, G., I, N., P, R., D, H., & L, H. (2019). Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: Comparison between European and non-European population. Dove Medical Press.
Style de citation Chicago (17e éd.)AJ, Savitz, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, et Hargarter L. Efficacy and Safety of Paliperidone Palmitate 3-month Versus 1-month Formulation in Patients with Schizophrenia: Comparison Between European and Non-European Population. Dove Medical Press, 2019.
Style de citation MLA (8e éd.)AJ, Savitz, et al. Efficacy and Safety of Paliperidone Palmitate 3-month Versus 1-month Formulation in Patients with Schizophrenia: Comparison Between European and Non-European Population. Dove Medical Press, 2019.